Anti-nr10 antibody and use thereof

Abstract

The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.

1 - 13 . (canceled) 
     
     
         14 . A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 1-3, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 5-7, respectively. 
     
     
         15 . A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO: 4. 
     
     
         16 . The purified antibody of  claim 15 , further comprising a light chain variable region comprising SEQ ID NO: 8. 
     
     
         17 . A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 8. 
     
     
         18 . A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 9-11, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 13-15, respectively. 
     
     
         19 . A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO: 12. 
     
     
         20 . The purified antibody of  claim 19 , further comprising a light chain variable region comprising SEQ ID NO: 16. 
     
     
         21 . A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 12 and a light chain variable region comprising SEQ ID NO: 16. 
     
     
         22 . A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 17-19, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 21-23, respectively. 
     
     
         23 . A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO: 20. 
     
     
         24 . The purified antibody of  claim 23 , further comprising a light chain variable region comprising SEQ ID NO: 24. 
     
     
         25 . A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 20 and a light chain variable region comprising SEQ ID NO: 24. 
     
     
         26 . A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 25-27, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 29-31, respectively. 
     
     
         27 . A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO: 28. 
     
     
         28 . The purified antibody of  claim 27 , further comprising a light chain variable region comprising SEQ ID NO: 32. 
     
     
         29 . A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 28 and a light chain variable region comprising SEQ ID NO: 32. 
     
     
         30 . A pharmaceutical composition comprising the antibody of  claim 14 . 
     
     
         31 . A pharmaceutical composition comprising the antibody of  claim 18 . 
     
     
         32 . A pharmaceutical composition comprising the antibody of  claim 22 . 
     
     
         33 . A pharmaceutical composition comprising the antibody of  claim 26 . 
     
     
         34 . The pharmaceutical composition of  claim 30 , further comprising a pharmaceutically acceptable carrier. 
     
     
         35 . The pharmaceutical composition of  claim 30 , comprising an ingredient selected from the group consisting of a surfactant, an excipient, an antioxidant, a coloring agent, a flavoring agent, a preservative, a stabilizer, a buffering agent, a chelating agent, a suspending agent, an isotonizing agent, a binder, a disintegrator, a lubricant, a fluidity promoter, and a corrigent. 
     
     
         36 . The pharmaceutical composition of  claim 30 , comprising an ingredient selected from the group consisting of light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmelose calcium, carmelose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylacetaldiethylaminoacetate, polyvinylpyrrolidone, gelatin, medium chain fatty acid triglyceride, polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethylcellulose, corn starch, and inorganic salt. 
     
     
         37 . The pharmaceutical composition of  claim 30 , comprising at least one low-molecular-weight polypeptide. 
     
     
         38 . The pharmaceutical composition of  claim 30 , comprising serum albumin or gelatin or both. 
     
     
         39 . The pharmaceutical composition of  claim 30 , further comprising at least one amino acid. 
     
     
         40 . The pharmaceutical composition of  claim 39 , wherein the at least one amino acid is selected from the group consisting of glycine, glutamine, asparagine, arginine, and lysine. 
     
     
         41 . The pharmaceutical composition of  claim 30 , wherein the composition is an isotonic aqueous solution suitable for injection. 
     
     
         42 . The pharmaceutical composition of  claim 41 , wherein the aqueous solution comprises physiological saline or dextrose or both. 
     
     
         43 . The pharmaceutical composition of  claim 41 , comprising an ingredient selected from the group consisting of D-sorbitol, D-mannose, D-mannitol, and sodium chloride. 
     
     
         44 . The pharmaceutical composition of  claim 30 , comprising a solubilizing agent. 
     
     
         45 . The pharmaceutical composition of  claim 44 , wherein the solubilizing agent is an alcohol, a polyalcohol, or a non-ionic detergent. 
     
     
         46 . The pharmaceutical composition of  claim 30 , comprising a microcapsule in which the antibody is encapsulated. 
     
     
         47 . The pharmaceutical composition of  claim 46 , wherein the microcapsule comprises hydroxymethylcellulose, gelatin, or polymethylmethacrylate. 
     
     
         48 . The pharmaceutical composition of  claim 30 , wherein the composition is a colloidal drug delivery system. 
     
     
         49 . The pharmaceutical composition of  claim 48 , wherein the colloidal drug delivery system is selected from the group consisting of liposomes, albumin microspheres, a microemulsion, nano-particles, and nano-capsules. 
     
     
         50 . The pharmaceutical composition of  claim 30 , wherein the composition is a sustained-release formulation. 
     
     
         51 . Nucleic acid of any one of (a) to (d) below:
 (a) nucleic acid encoding an antibody that recognizes domain 1 of NR10;   (b) an isolated nucleic acid encoding a protein comprising the amino acid sequence of any one of SEQ ID NOs: 1-32;   (c) an isolated nucleic acid encoding a protein that (i) comprises the amino acid sequence of any one of SEQ ID NOs: 1-32 in which one or more amino acids are replaced, deleted, inserted and/or added and (ii) binds to the same epitope as is bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 8, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 12 and a light chain variable region comprising SEQ ID NO: 16, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 20 and a light chain variable region comprising SEQ ID NO: 24, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 28 and a light chain variable region comprising SEQ ID NO: 32; and   (d) an isolated nucleic acid that (i) hybridizes under stringent conditions with the nucleotide sequence of any one of SEQ ID NOs: 1-32, and (ii) encodes a polypeptide that binds to the same epitope as is bound an antibody comprising a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 8, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 12 and a light chain variable region comprising SEQ ID NO: 16, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 20 and a light chain variable region comprising SEQ ID NO: 24, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 28 and a light chain variable region comprising SEQ ID NO: 32.   
     
     
         52 . A vector or vectors comprising the nucleic acid of  claim 51 . 
     
     
         53 . A host cell containing the vector or vectors of  claim 52 . 
     
     
         54 . A method for producing a protein or an antibody, the method comprising culturing the host cell of  claim 53  so that the protein or antibody encoded on the vector or vectors is expressed. 
     
     
         55 . A method for producing an anti-NR10 antibody, the method comprising providing a cell containing recombinant nucleic acid encoding an antibody that recognizes domain 1 of NR10 and culturing the cell in vitro so that the antibody is expressed by the cell. 
     
     
         56 . A composition comprising an antibody that recognizes domain 1 of NR10, the antibody being covalently linked to a molecule selected from the group consisting of a polymeric substance, hyaluronic acid, a radioactive substance, a fluorescent substance, a luminescent substance, an enzyme, and a toxin. 
     
     
         57 . A method for obtaining the composition of  claim 56 , the method comprising chemically conjugating the molecule to an antibody that recognizes domain 1 of NR10. 
     
     
         58 . A method for measuring the activity of an anti-NR10 antibody, the method comprising contacting the antibody with cells of an interleukin 31 (IL-31)-dependent cell line and determining whether the antibody suppresses growth of the cells. 
     
     
         59 . A method for determining the NR10-binding activity of an anti-NR10 antibody, the method comprising use of a technique selected from ELISA (enzyme-linked immunosorbent assay), EIA (enzyme immunoassay), RIA (radioimmunoassay) and fluorescent antibody assay to determine the NR10-binding activity of the anti-NR10 antibody. 
     
     
         60 . The method of  claim 59 , wherein the method comprises use of an enzyme immunoassay that comprises:
 (a) contacting a sample containing an anti-NR10 antibody with an NR10-coated plate;   (b) adding to the plate a secondary antibody that is labeled with an enzyme, wherein the secondary antibody binds to the anti-NR10 antibody;   (c) incubating the plate with the antibodies;   (d) washing the plate;   (e) adding a substrate for the enzyme to the plate; and   (f) measuring absorbance to detect enzymatic alteration of the substrate, as a measure of the NR10-binding activity of the anti-NR10 antibody.   
     
     
         61 . A method for treating or preventing an inflammatory disease in a subject in recognized need thereof, the method comprising administering to the subject an antibody that recognizes domain 1 of NR10. 
     
     
         62 . The method of  claim 61 , wherein the inflammatory disease is a disease with pathological features involved in cytological and histological reactions that occur in affected blood vessels and adjacent tissues in response to an injury or abnormal stimulation caused by a physical, chemical, or biological agent. 
     
     
         63 . A method for isolating and purifying an antibody that recognizes domain 1 of NR10, the method comprising subjecting a sample comprising the antibody to a method comprising a combination of multiple techniques selected from column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectrofocusing, dialysis, and recrystallization. 
     
     
         64 . The method of  claim 63 , wherein the method comprises a column chromatography technique selected from the group consisting of affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography. 
     
     
         65 . The method of  claim 64 , wherein the column chromatography technique comprises affinity chromatography using a protein A column or a protein G column. 
     
     
         66 . An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 196, 197, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively. 
     
     
         67 . An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 9, 197 and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively. 
     
     
         68 . An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 176, 197, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively. 
     
     
         69 . An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 9, 198, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively. 
     
     
         70 . An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 176, 198, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively. 
     
     
         71 . An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 9, 199, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 203, 170, and 193, respectively. 
     
     
         72 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 206. 
     
     
         73 . The antibody of  claim 72 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         74 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 207. 
     
     
         75 . The antibody of  claim 74 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         76 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 208. 
     
     
         77 . The antibody of  claim 76 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         78 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 209. 
     
     
         79 . The antibody of  claim 78 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         80 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 210. 
     
     
         81 . The antibody of  claim 80 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         82 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 211. 
     
     
         83 . The antibody of  claim 82 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         84 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 212. 
     
     
         85 . The antibody of  claim 84 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         86 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 213. 
     
     
         87 . The antibody of  claim 86 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         88 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 214. 
     
     
         89 . The antibody of  claim 88 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         90 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 215. 
     
     
         91 . The antibody of  claim 90 , comprising a light chain variable region comprising SEQ ID NO: 220. 
     
     
         92 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 216. 
     
     
         93 . The antibody of  claim 92 , comprising a light chain variable region comprising SEQ ID NO: 221. 
     
     
         94 . An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 217. 
     
     
         95 . The antibody of  claim 94 , comprising a light chain variable region comprising SEQ ID NO: 221. 
     
     
         96 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 224. 
     
     
         97 . The antibody of  claim 96 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         98 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 225. 
     
     
         99 . The antibody of  claim 98 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         100 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 226. 
     
     
         101 . The antibody of  claim 100 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         102 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 227. 
     
     
         103 . The antibody of  claim 102 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         104 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 228. 
     
     
         105 . The antibody of  claim 104 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         106 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 229. 
     
     
         107 . The antibody of  claim 106 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         108 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 230. 
     
     
         109 . The antibody of  claim 108 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         110 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 231. 
     
     
         111 . The antibody of  claim 110 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         112 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 232. 
     
     
         113 . The antibody of  claim 112 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         114 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 233. 
     
     
         115 . The antibody of  claim 114 , comprising a light chain comprising SEQ ID NO: 238. 
     
     
         116 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 234. 
     
     
         117 . The antibody of  claim 116 , comprising a light chain comprising SEQ ID NO: 239. 
     
     
         118 . An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 235. 
     
     
         119 . The antibody of  claim 118 , comprising a light chain comprising SEQ ID NO: 239. 
     
     
         120 . An anti-NR10 antibody that comprises a light chain variable region comprising SEQ ID NO: 220. 
     
     
         121 . An anti-NR10 antibody that comprises a light chain variable region comprising SEQ ID NO: 221. 
     
     
         122 . An anti-NR10 antibody that comprises a light chain comprising SEQ ID NO: 238. 
     
     
         123 . An anti-NR10 antibody that comprises a light chain comprising SEQ ID NO: 239. 
     
     
         124 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 206 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         125 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 207 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         126 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 208 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         127 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 209 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         128 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 210 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         129 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 211 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         130 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 212 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         131 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 213 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         132 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 214 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         133 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 215 and a light chain variable region comprising SEQ ID NO: 220. 
     
     
         134 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 216 and a light chain variable region comprising SEQ ID NO: 221. 
     
     
         135 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 217 and a light chain variable region comprising SEQ ID NO: 221. 
     
     
         136 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 224 and a light chain comprising SEQ ID NO: 238. 
     
     
         137 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 225 and a light chain comprising SEQ ID NO: 238. 
     
     
         138 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 226 and a light chain comprising SEQ ID NO: 238. 
     
     
         139 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 227 and a light chain comprising SEQ ID NO: 238. 
     
     
         140 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 228 and a light chain comprising SEQ ID NO: 238. 
     
     
         141 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 229 and a light chain comprising SEQ ID NO: 238. 
     
     
         142 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 230 and a light chain comprising SEQ ID NO: 238. 
     
     
         143 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 231 and a light chain comprising SEQ ID NO: 238. 
     
     
         144 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 232 and a light chain comprising SEQ ID NO: 238. 
     
     
         145 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 233 and a light chain comprising SEQ ID NO: 238. 
     
     
         146 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 234 and a light chain comprising SEQ ID NO: 239. 
     
     
         147 . A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 235 and a light chain comprising SEQ ID NO: 239. 
     
     
         148 . A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 1. 
     
     
         149 . A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 9. 
     
     
         150 . A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 17. 
     
     
         151 . A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 25. 
     
     
         152 . A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 196. 
     
     
         153 . A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 176. 
     
     
         154 . A method of inhibiting the activity of NR10 comprising contacting the NR10 with an antibody that recognizes domain 1 of NR10. 
     
     
         155 . A method of neutralizing the activity of interleukin 31 in a subject in recognized need thereof, the method comprising introducing into the subject an antibody that recognizes domain 1 of NR10. 
     
     
         156 . A method for determining the NR10-binding activity of an antibody that recognizes domain 1 of NR10, the method comprising contacting the antibody with a polypeptide comprising domain 1 of NR10 and determining whether the antibody binds to the polypeptide. 
     
     
         157 . A method for manufacturing an antibody that recognizes domain 1 of NR10, the method comprising making the antibody and assaying whether it binds to a polypeptide comprising domain 1 of NR10. 
     
     
         158 . A method for manufacturing an antibody that recognizes domain 1 of NR10, the method comprising making the antibody and assaying whether it inhibits a biological activity of interleukin 31. 
     
     
         159 . A hybridoma producing a glycosylated antibody that recognizes domain 1 of NR10. 
     
     
         160 . A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising the heavy chain variable region of SEQ ID NO: 12. 
     
     
         161 . The purified antibody of  claim 160 , wherein the reference antibody comprises the heavy chain variable region of SEQ ID NO: 12 and the light chain variable region of SEQ ID NO: 16. 
     
     
         162 . The purified antibody of  claim 160 , wherein the purified antibody comprises the heavy chain variable region of SEQ ID NO: 12. 
     
     
         163 . The purified antibody of  claim 162 , wherein the purified antibody further comprises the light chain variable region of SEQ ID NO: 16. 
     
     
         164 . A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 9, 10, and 11, and a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15. 
     
     
         165 . The purified antibody of  claim 164 , wherein the purified antibody comprises:
 a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 9, 10, and 11; and   a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15.   
     
     
         166 . A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising the heavy chain variable region of SEQ ID NO: 28. 
     
     
         167 . The purified antibody of  claim 166 , wherein the reference antibody comprises the heavy chain variable region of SEQ ID NO: 28 and the light chain variable region of SEQ ID NO: 32. 
     
     
         168 . The purified antibody of  claim 166 , wherein the purified antibody comprises the heavy chain variable region of SEQ ID NO: 28. 
     
     
         169 . The purified antibody of  claim 168 , wherein the purified antibody further comprises the light chain variable region of SEQ ID NO: 32. 
     
     
         170 . A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27, and a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 29, 30, and 31. 
     
     
         171 . The purified antibody of  claim 170 , wherein the purified antibody comprises:
 a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27; and   a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 29, 30, and 31.